Market Overview

UPDATE: Citigroup Upgrades Acorda Therapeutics to Buy on Limited Downside, Catalysts

Share:
Related ACOR
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1
J.P Morgan Just Chimed In With Ratings On Biotech Stocks

Citigroup raised its rating on Acorda Therapeutics (NASDAQ: ACOR) from Neutral to Buy and raised its price target from $28 to $33.

Citigroup said, "We expect Ampyra to continue to grow fueled by modest market share gains and price increases. We project a 10% price increase in Q1:13 and 5% annually thereafter as there is still pricing power for the brand. This is overlooked by investors and should drive Ampyra's growth. We see limited downside to the stock as the stock is undervalued based on DCF esp. after its poor performance in 2012."

Acorda Therapeutics closed at $24.86 on Wednesday.

Latest Ratings for ACOR

DateFirmActionFromTo
Jan 2015CitigroupMaintainsNeutral
Dec 2014Goldman SachsInitiates Coverage onNeutral
Oct 2014CitigroupMaintainsNeutral

View More Analyst Ratings for ACOR
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (ACOR)

Around the Web, We're Loving...

Get Benzinga's Newsletters